Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR20750] to LOX 1 - BSA and Azide free
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Product nameAnti-LOX 1 antibody [EPR20750] - BSA and Azide free
See all LOX 1 primary antibodies
DescriptionRabbit monoclonal [EPR20750] to LOX 1 - BSA and Azide free
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human LOX 1 aa 50-150. The exact sequence is proprietary.
Database link: P78380
- WB: Human fetal vessel lysate; Mouse placenta and lung lysates; Rat placenta lysate.
Ab234962 is the carrier-free version of ab214427. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
ab234962 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferpH: 7.2
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab234962 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Detects a band of approximately 52 kDa (predicted molecular weight: 31 kDa).|
FunctionReceptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
Tissue specificityExpressed at high level in endothelial cells and vascular-rich organs such as placenta, lung, liver and brain, aortic intima, bone marrow, spinal cord and substantia nigra. Also expressed at the surface of dendritic cells. Widely expressed at intermediate and low level.
Involvement in diseaseNote=Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility.
Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.
Sequence similaritiesContains 1 C-type lectin domain.
DomainThe cytoplasmic region is required for subcellular sorting on the cell surface.
The C-type lectin domain mediates the recognition and binding of oxLDL.
modificationsThe intrachain disulfide-bonds prevent N-glycosylation at some sites.
Cellular localizationCell membrane. Secreted. A secreted form also exists.
- Information by UniProt
- C-type lectin domain family 8 member A antibody
- CLEC8A antibody
- hLOX 1 antibody
All lanes : Anti-LOX 1 antibody [EPR20750] (ab214427) at 1/1000 dilution
Lane 1 : Human fetal vessel lysate
Lane 2 : Mouse placenta lysate
Lane 3 : Mouse lung lysate
Lane 4 : Rat placenta lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 31 kDa
Observed band size: 52 kDa why is the actual band size different from the predicted?
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time : Lanes 1-4: 3 minutes; Lane 5: 15 seconds.
The expression profile is consistent with what has been described in the literature (PMID: 10692464, PMID: 15016631).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab214427).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab234962 has not yet been referenced specifically in any publications.